Drug profile · INN
mavacamten
CAMZYOS
mavacamten (CAMZYOS) is a cardiac myosin inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — mavacamten
- US status
- approved
- Class
- Cardiovascular system (C01)
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
mavacamten (CAMZYOS) is a cardiac myosin inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cardiac myosin inhibitor
Primary target: Cardiac myosin
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is mavacamten?
mavacamten (CAMZYOS) is a cardiac myosin inhibitor. Associated with Bristol-Myers Squibb Australia Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for mavacamten?
CAMZYOS is a marketed brand name for mavacamten. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mavacamten?
mavacamten has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.